Articles

Existing Oral and IV Therapies

ASH 2015 – Multiple Myeloma

Ali McBride discusses medicines that have been on the market for the last few years. Read More ›

Getting New Therapies to Patients

ASH 2015 – Multiple Myeloma

Ali McBride speaks to the challenges of medication adherence, especially in the various settings. Read More ›

Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

The Pharmacist and Oral Oncolytics

ASH 2015 – Multiple Myeloma

R. Donald Harvey discusseses his role in managing patients on this medication class. Read More ›

Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Patient Access to Oral Oncolytics

ASH 2015 – Multiple Myeloma

Ali McBride talks about patient issues with medication adherence and what payers are doing to ensure compliance. Read More ›

R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Page 131 of 147